Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells

Vaccine

Volumn 27, Issue 46, 2009, Pages 6415-6419

  Nallet, Sophie ^a   Amacker, Mario ^b   Westerfeld, Nicole ^b   Baldi, Lucia ^a   König, Iwo ^c   Hacker, David L ^a   Zaborosch, Christiane ^c   Zurbriggen, Rinaldo ^b   Wurm, Florian M ^a  

^a EPFL   (Switzerland)

^b Pevion Biotech Ltd   (Switzerland)

^c ZURICH UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

Author keywords

Recombinant protein; RSV vaccine; Transient transfection; Virosomes

Indexed keywords

HYBRID PROTEIN; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; POLYETHYLENEIMINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIROSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BIOREACTOR; CELL CULTURE; CELL STRAIN HEK293; CONTROLLED STUDY; COTTON RAT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; TRANSFECTION; VACCINES, SUBUNIT; VIRAL FUSION PROTEINS; VIROSOMES;

EID: 70350075814     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.019     Document Type: Article

References (27)

1. Falsey A.R., and Walsh E.E. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13 July (3) (2000) 371-384
2. Law B.J., Carbonell-Estrany X., and Simoes E.A. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 96 April (Suppl. B) (2002) S1-S7
3. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., and Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89 April (4) (1969) 405-421
4. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 April (4) (1969) 422-434
5. Hall C.B., Walsh E.E., Long C.E., and Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163 4 (1991) 693-698
6. Henderson F.W., Collier A.M., Clyde W.A.J., and Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 300 10 (1979) 530-534
7. Collins P.L., and Murphy B.R. Vaccines against human respiratory syncytial virus. In: Cane P. (Ed). Respiratory Syncytial Virus (2007), Elsevier, Amsterdam 233-277
8. van Drunen Littel-van den Hurk S., Mapletoft J.W., Arsic N., and Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17 1 (2007) 5-34
9. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 21 (2003) 921-924
10. Cusi M.G., Zurbriggen R., Correale P., Valassina M., Terrosi C., Pergola L., et al. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine 20 October (29-30) (2002) 3436-3442
11. Barnes L.M., and Dickson A.J. Mammalian cell factories for efficient and stable protein expression. Curr Opin Biotechnol 17 August (4) (2006) 381-386
12. González-Reyes L., Ruiz-Argüello M.B., García-Barreno B., Calder L., López J.A., Albar J.P., et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 98 August (17) (2001) 9859-9864
13. Baldi L., Hacker D., Adam M., and Wurm F.M. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 29 5 (2007) 677-684
14. Ternette N., Stefanou D., Kuate S., Uberla K., and Grunwald T. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol J 4 (2007) 51
15. Muller N., Girard P., Hacker D.L., Jordan M., and Wurm F.M. Orbital shaker technology for the cultivation of mammalian cells in suspension. Biotechnol Bioeng 89 February (4) (2005) 400-406
16. Stettler M., Jaccard N., Hacker D., De Jesus M., Wurm F.M., and Jordan M. New disposable tubes for rapid and precise biomass assessment for suspension cultures of mammalian cells. Biotechnol Bioeng 95 December (6) (2006) 1228-1233
17. De Jesus M., Girard P., Bourgeois M., Baumgartner G., Jacko B., Amstutz H., et al. TubeSpin satellites: a fast track approach for process development with animal cells using shaking technology. Biochem Eng J 17 (2004) 217-223
18. Stettler M., Zhang X., Hacker D.L., DeJesus M., and Wurm F.M. Novel orbital shake bioreactors for transient production of CHO derived IgGs. Biotechnol Prog 23 6 (2007) 1340-1346
19. Hancock G.E., Hahn D.J., Speelman D.J., Hildreth S.W., Pillai S., and McQueen K. The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus. Vaccine 12 3 (1994) 267-274
20. Kammer A.R., Amacker M., Rasi S., Westerfeld N., Gremion C., Neuhaus D., et al. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine 25 October (41) (2007) 7065-7074
21. Amacker M., Engler O., Kammer A.R., Vadrucci S., Oberholzer D., Cerny A., et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol 17 June (6) (2005) 695-704
22. Junge F., Schneider B., Reckel S., Schwarz D., Dötsch V., and Bernhard F. Large-scale production of functional membrane proteins. Cell Mol Life Sci 65 11 (2008) 1729-1755
23. Sarramegna V., Talmont F., Demange P., and Milon A. Heterologous expression of G-protein-coupled receptors: comparison of expression systems from the standpoint of large-scale production and purification. Cell Mol Life Sci 60 August (8) (2003) 1529-1546
24. Shi C., Shin Y.O., Hanson J., Cass B., Loewen M.C., and Durocher Y. Purification and characterization of a recombinant G-protein-coupled receptor, Saccharomyces cerevisiae Ste2p, transiently expressed in HEK293 EBNA1 cells. Biochemistry 44 December (48) (2005) 15705-15714
25. Pham P.L., Kamen A., and Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol 34 2 (2006) 225-237
26. Geisse S., Jordan M., and Wurm F. Large-scale transient expression of therapeutic proteins in mammalian cells. Methods Mol Biol 308 (2005) 87-98
27. Soler E., Houdebine L.-M., and El-Gewely M.R. Preparation of recombinant vaccines. Biotechnol Ann Rev: Elsevier (2007) 65-94